Clinical trials: Throat Carcinoma
Recurrent Oropharynx Carcinoma
Changes to Function and Quality of Life and Patient Experience for Patients Undergoing Treatments for Recurrent Oropharyngeal Cancer
The purpose of this research project is to measure changes in communication, swallowing and quality of life and individual patient priorities which may happen over time in patients with a diagnosis of recurrent head and neck…
- Trial name
- FUNQOLR (NCT04952922)
- Testing
- Treatment for recurrent oropharyngeal cancer (curative/ palliative)
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Histopathological Diagnosis of Nasopharyngeal Carcinoma, Patients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition
Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma
In our previous retrospective study, we identified circulating immune cell counts and the CD4/CD8 ratio as significant prognostic markers in nasopharyngeal carcinoma.
- Trial name
- NCT06762470
- Where
- China
- Volunteers
- 325 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Head and Neck Cancer, Carcinoma, Squamous Cell
Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
- Conditions
- Head and Neck Cancer, Carcinoma, Squamous Cell, Neoplasms, Oral, Neoplasms, Pharyngeal
- Trial name
- INFIELD (NCT03067610)
- Testing
- Intensity Modulated Radiation Therapy, chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Texas Southwestern Medical Center
Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to evaluate the efficacy and safety of single-agent Becotatug Vedotin as adjuvant therapy in patients with…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Locoregionally Advanced Nasopharyngeal Carcinoma, Adjuvant Therapy
- Trial name
- NCT07303283
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Kai Hu
Nasopharyngeal Carcinoma
A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Locoregionally advanced nasopharyngeal carcinoma (NPC)(stage III, IV in UICC 2002 Classification) can be divided into two groups according to the risk of metastasis: high-risk metastasis group (T4 or N2-3) and low-risk metastasis…
- Trial name
- NCT00705627
- Testing
- neoadjuvant chemotherapy plus concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma
Epstein-Barr virus (EBV) has been proven to process a strong association in patient of nasopharyngeal carcinoma (NPC). Monitoring plasma EBV DNA in NPC patients can provide reliable informations in early detecting tumor…
- Trial name
- NCT03087695
- Testing
- Plasma EBV DNA
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Taichung Veterans General Hospital
Oropharyngeal Carcinoma
Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy
This study is a prospective phase II trial which is designed to evaluate the efficacy and safety of IMRT combined with concurrent chemotherapy and anti-EGFR monoclonal antibody in locally advanced oropharyngeal carcinoma (OPC)…
- Trial name
- NCT04508829
- Testing
- Anti-EGFR monoclonal antibody
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Fudan University
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
Metastatic Nasopharyngeal Carcinoma
Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment
to evaluate the efficacy and safety of toripalimab and capecitabine maintenance therapy in patients with metastatic nasopharyngeal carcinoma (NPC) after first-line gemcitabine/cisplatin combined with toripalimab.
- Trial name
- NCT05484375
- Testing
- Capecitabine plus toripalimab
- Volunteers
- 40 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Head and Neck Squamous Carcinoma, Nasopharyngeal Carcinoma
Trial of E10A in Head and Neck Cancer
Angiogenesis, the formation of new blood vessel from existing vessels, is essential for tumor growth and metastasis. Antiangiogenic therapies inhibit the growth of genetically stable endothelial cells, and most tumors should…
- Trial name
- NCT00634595
- Testing
- E10A, Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Sun Yat-sen University
Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic…
- Trial name
- NCT06331845
- Testing
- Gemcitabine, Cisplatin, Paclitaxel protein-bound
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma, Metastasis
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
The treatment of distant metastasis is a key challenge for nasopharyngeal carcinoma because of poor outcomes, among which, chemotherapy is the cornerstone.
- Conditions
- Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy
- Trial name
- NCT04890522
- Testing
- Triprilimab(JS001), Cisplatin, 5-Fluorouracil
- Where
- China
- Volunteers
- 622 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
Through a prospective clinical trial, we intend to combine surgery, induction chemotherapy, target-reduction intensity-modulated radiotherapy and concurrent chemotherapy as an experimental treatment for patients with newly…
- Trial name
- NCT05352321
- Testing
- Gemcitabine, Cisplatin, regular intensity-modulated radiotherapy
- Where
- 2 sites in China
- Volunteers
- 264 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy
This study is a prospective phase II trial which is designed to evaluate the efficacy and safety of IMRT combined with concurrent chemotherapy and anti-EGFR monoclonal antibody in locally advanced nasopharyngeal carcinoma with…
- Trial name
- NCT04508816
- Testing
- cetuximab (CTX) or nimotuzumab (NTZ)
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma
In this exploratory clinical trial, patients with newly diagnosed distant metastatic nasopharyngeal carcinoma were treated with gemcitabine+ cisplatin+PD-1 inhibitor regimen followed by whole-target radiotherapy (IMRT for local…
- Trial name
- NCT05431764
- Testing
- Camrelizumab, gemcitabin, cisplatin, Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC), Osteoradionecrosis of the Jaw
Impacted Tooth Management and Osteoradionecrosis Risk in NPC
This multicenter, randomized controlled trial is designed to determine whether omitting prophylactic extraction of impacted teeth before radiotherapy leads to an unacceptably higher risk of jaw osteoradionecrosis (JORN) compared…
- Trial name
- NCT07764887
- Testing
- Omission of Prophylactic Impacted Tooth Extraction, Prophylactic Impacted Tooth Extraction
- Where
- 11 sites in China
- Volunteers
- 536 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Cancer Recurrent
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
- Trial name
- TRANSPARENT (NCT06457503)
- Testing
- Toripalimab, Cisplatin, Gemcitabine
- Where
- 13 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Coherus Oncology, Inc.
Hypopharyngeal Carcinoma, Laryngeal Carcinoma
Interest of MRI in Preoperative Staging for the Laryngeal and Hypopharyngeal Cancer
To determine if MRI can detect preoperative invasion of cartilage by laryngeal and hypopharyngeal carcinoma, and to compare it to CT imaging and histopathology in excised larynges and/or hypopharynges.
- Trial name
- Larynx MRI (NCT03132727)
- Testing
- Pharyngo laryngeal MRI
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Hospices Civils de Lyon
Cancer of the Head and Neck, Oropharynx Cancer
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
This trial will explore giving standard dose chemotherapy and radiation therapy to sites of disease including all lymph nodes involved with HPV-positive oropharyngeal cancer, but administer lower doses of radiation therapy to the…
- Conditions
- Cancer of the Head and Neck, Oropharynx Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Throat Carcinoma
- Trial name
- ENID (NCT04444869)
- Testing
- Cisplatin injection
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Missouri-Columbia
Head and Neck Neoplasms
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell…
- Trial name
- NCT01087970
- Testing
- Pemetrexed, Cetuximab, Carboplatin
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.